✦ LIBER ✦

Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

✍ Scribed by K. Esposito; D. Cozzolino; G. Bellastella; M. I. Maiorino; P. Chiodini; A. Ceriello; D. Giugliano

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dipeptidyl peptidase-4 inhibitors in the

✍ C. F. Deacon 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 711 KB

Efficacy and safety of the dipeptidyl pe

✍ R. E. Pratley; M. S. Kipnes; P. R. Fleck; C. Wilson; Q. Mekki; Alogliptin Study 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

Efficacy and safety of the dipeptidyl pe

✍ M. A. Nauck; G. Meininger; D. Sheng; L. Terranella; P. P. Stein; Sitagliptin Stu 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB

Effect of adding sitagliptin, a dipeptid

✍ R. Brazg; L. Xu; C. Dalla Man; C. Cobelli; K. Thomas; P. P. Stein 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

Achieving a clinically relevant composit

✍ B. Zinman; W. E. Schmidt; A. Moses; N. Lund; S. Gough 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 534 KB

Efficacy and safety of the dipeptidyl pe

✍ K. Hermansen; M. Kipnes; E. Luo; D. Fanurik; H. Khatami; P. Stein; Sitagliptin S 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB